Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.58 |
| ▸ | MC3R | P41968 | 7/20 | 0.56 |
| ▸ | MC5R | P33032 | 6/20 | 0.56 |
| ▸ | MC1R | Q01726 | 5/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21035853 | 0.93 | MC4R (0.61) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL20994306 | 0.89 | MC4R (0.59) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL28646063 | 0.89 | MC4R (0.63) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL21124303 | 0.84 | MC4R (0.54) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL21123989 | 0.84 | MC4R (0.59) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL21123794 | 0.83 | MC4R (0.57) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL21029714 | 0.83 | MC4R (0.68) | MC4R | |
| SCHEMBL21124447 | 0.82 | MC4R (0.59) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL21124305 | 0.82 | MC4R (0.58) | MC4RMC3RMC5RMC1RKCNH2 | |
| SCHEMBL21124449 | 0.82 | MC4R (0.58) | MC4RMC3RMC5RMC1RKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-10710988-B2 | Piperazine derivative | ASTELLAS PHARMA INC. (JP) | 2020-07-14 | — | — | US | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2019-07-04 | — | — | US | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10710988-B2 | Piperazine derivative | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 14/4885MC5R 6/4885 |
| US-20190202815-A1 | PIPERAZINE DERIVATIVE | GPR4, MC4R, TRPC4 | MC4R 2/4885MC3R 14/4885MC5R 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.